Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

Infants with cardiopulmonary disease develop severe illness from respiratory syncytial virus (RSV) infection. Safety, feasibility, and pharmacokinetics of intravenous gamma globulin (IVIG) to prevent RSV illness were studied in 23 high-risk infants in a phase I trial. IVIG with an RSV neutralizing a...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Groothuis, J R, Levin, M J, Rodriguez, W, Hall, C B, Long, C E, Kim, H W, Lauer, B A, Hemming, V G
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1991
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC245192/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1718213/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.35.7.1469
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!